Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins sits in the top decile of US sponsors by registered trial count (#69 of 15,742 sponsors by registered trial count).
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins: 523 sponsored US clinical trials, 69 recruiting.
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins sponsors 523 registered US clinical trials on ClinicalTrials.gov, 69 of them currently recruiting, and 301 completed. 5 of these trials are in Phase 3-4 (later-stage) and 395 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Prostate Cancer, with 17 trials.
Top-decile sponsor footprint
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins ranks in the top decile of sponsors by registered trial count (#69 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
301 of 415 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (72.5%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
523 total, page 5 of 11
Phase 2 Study of Nivolumab in Solid Tumors Induced by Prior Radiation Exposure
NCT02864316
Nonmyeloablative Conditioning and Transplantation for Patients With Refractory Systemic Lupus Erythematosus (SLE)
NCT02080195
NMA Haplo or MUD BMT for Newly Diagnosed Severe Aplastic Anemia
NCT02833805
Anti-LAG-3 Alone & in Combination w/ Nivolumab Treating Patients w/ Recurrent GBM (Anti-CD137 Arm Closed 10/16/18)
NCT02658981
Comparison of PSMA-based 18F-DCFPyL PET/CT to Conventional Imaging in the Evaluation of Patients With Castration-Resistant Prostate Cancer
NCT02856100
Study With CY, Pembrolizumab, GVAX Pancreas Vaccine, and SBRT in Patients With Locally Advanced Pancreatic Cancer
NCT02648282
Study of Azacitidine in Combination With Pembrolizumab in R/R AML Patients and in Newly Diagnosed Older Patients
NCT02845297
Pilot Study of Mobilization and Treatment of Disseminated Tumor Cells in Men With Metastatic Prostate Cancer
NCT02478125
SRS and Nivolumab in Treating Patients With Newly Diagnosed Melanoma Metastases in the Brain or Spine
NCT02716948
Docetaxel With or Without Ascorbic Acid in Treating Patients With Metastatic Prostate Cancer
NCT02516670
Study of the Clinical Utility of PSMA Imaging in the Evaluation of Men With Prostate Cancer
NCT02825875
A Study of Definitive Therapy to Treat Prostate Cancer
NCT02716974
Evaluation of 18F-DCFPyL PSMA- Versus 18F-NaF-PET Imaging for Detection of Metastatic Prostate Cancer.
NCT03497377
Phase I Study of Mebendazole Therapy for Recurrent/Progressive Pediatric Brain Tumors
NCT02644291
Ultrasound Monitoring of Abdominal Soft Tissue
NCT02722616
Stereotactic Body Radiation for Prostate Oligometastases
NCT02680587
Biomarker-Driven Therapy With Nivolumab and Ipilimumab in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Expressing AR-V7
NCT02601014
Study of Sipuleucel-T W/ or W/O Radium-223 in Men With Asymptomatic or Minimally Symptomatic Bone-MCRPC
NCT02463799
A Study of Enhancing Response to MK-3475 in Advanced Colorectal Cancer
NCT02512172
Study of Neoadjuvant Nivolumab in Patients With Non-metastatic Stage II-IV Clear Cell Renal Cell Carcinoma
NCT02575222
Vibrent Smartphone Mobile Application
NCT02421536
Study of Tremelimumab Alone or Combined With Olaparib for Patients With Persistent EOC (Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma)
NCT02485990
Pembrolizumab and Cryosurgery in Treating Patients With Newly Diagnosed, Oligo-metastatic Prostate Cancer
NCT02489357
Shorter Course Tacro After NMA, Related Donor PBSCT With High-dose Posttransplant Cy for Hard-to-Engraft Malignancies
NCT02556931
Simplifying Survivorship Care Planning
NCT03035773
Dexamethasone Prior to Re-treatment With Enzalutamide in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Previously Treated With Enzalutamide and Docetaxel
NCT02491411
Myeloablative Haploidentical BMT With Post-transplant Cyclophosphamide for Pediatric Patients With Hematologic Malignancies
NCT02120157
A Safety Study of Fingolimod With Radiation and Temozolomide in Newly Diagnosed High Grade Glioma
NCT02490930
Utilizing Advance Care Planning Videos to Empower Perioperative Cancer Patients and Families
NCT02489799
Pilot Study of 18F-DCFPyL PET/CT in the Evaluation of Men With an Elevated PSA Following Radical Prostatectomy
NCT02523924
Adoptive Immunotherapy With Activated Marrow Infiltrating Lymphocytes and Cyclophosphamide Graft-Versus-Host Disease Prophylaxis in Patients With Relapse of Hematologic Malignancies After Allogeneic Hematopoietic Cell Transplantation
NCT02342613
Survivorship Promotion In Reducing IGF-1 Trial
NCT02431676
Randomized Salvage Radiation Therapy Plus Enzalutamide Post Prostatectomy
NCT02203695
FBnTP Imaging of Breast Cancer
NCT02204462
Scrambler Therapy in the Treatment of Chronic Chemotherapy-Induced Peripheral Neuropathy
NCT02111174
Targeted Imaging of Glutamate Carboxypeptidase II With DCFPyL-PET
NCT03542773
Intravaginal Artesunate for the Treatment of HPV+ High Grade Cervical Intraepithelial Neoplasia (CIN2/3)
NCT02354534
Patient and Provider Initiated Survivorship Care Planning
NCT02405819
Brain Interstitium Temozolomide Concentration Pre and Post Regadenoson Administration
NCT02389738
Study of Gemcitabine/Taxotere/Xeloda (GTX) in Combination With Cisplatin and Irinotecan in Subjects With Metastatic Pancreatic Cancer
NCT02324543
Immunologic Responses in HPV-Associated Carcinoma for Patients Receiving Chemoradiation
NCT01958515
GVAX Pancreas Vaccine (With CY) and CRS-207 With or Without Nivolumab
NCT02243371
Testosterone Revival Abolishes Negative Symptoms, Fosters Objective Response and Modulates Enzalutamide Resistance
NCT02286921
Cancer DNA Detection in Blood and Urine
NCT02657863
Intraoperative Dosimetry for Prostate Brachytherapy Using Fluoroscopy and Ultrasound
NCT02225925
RE-sensitizing With Supraphysiologic Testosterone to Overcome REsistance (The RESTORE Study)
NCT02090114
Transplantation of Partially Mismatched Related or Matched Unrelated Bone Marrow for Patients With Refractory Severe Aplastic Anemia
NCT02224872
Pilot Study Using Amide Proton Transfer Magnetic Resonance Imaging Distinguishing Glioma
NCT03843814
Nelfinavir for the Treatment of Gammaherpesvirus-Related Tumors
NCT02080416
Chemoradiation or Brachytherapy for Rectal Cancer
NCT02017704
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 185 |
| Phase 2 | 210 |
| Phase 3 | 5 |
Therapeutic Areas
What is open in the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins pipeline
69 recruiting of 523 indexed (13% open); 301 completed (58%).
Phase mix: 5 late (III/IV) vs 395 early (I/II) (early-phase heavy).
Top condition: Prostate Cancer (17 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins: open-pipeline peers nationwide
Peers matched on 523 registered trials and 13% open enrollment, not the therapeutic-area sidebar.
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 523 trials (± recruiting share)
- AbbVie · 526 trials · 21% recruiting
- Boehringer Ingelheim · 515 trials · 8% recruiting
- Gilead Sciences · 504 trials · 5% recruiting
- H. Lee Moffitt Cancer Center and Research Institute · 502 trials · 16% recruiting
Sponsors near 13% open enrollment (± trial volume)
- MetroHealth Medical Center · 13% recruiting · 76 trials
- Texas Tech University Health Sciences Center · 13% recruiting · 76 trials
- Chiesi Farmaceutici S.p.A. · 13% recruiting · 30 trials
- Dizal Pharmaceuticals · 13% recruiting · 15 trials
Related
What to do with this Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins page
523 registered trials is a research-attention snapshot, not an endorsement of Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins or any single study.
- 69 of Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Prostate Cancer is the condition Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Prostate Cancer trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins pipeline card: 523 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.